The U.S. Department of Health and Human Services said Thursday that it is restricting the use of COVID-19 Johnson & Johnson drugs for adults due to the risk of rare hemorrhagic fever, new relapses in the cerebral palsy. -sold horn covered.
The J&J vaccine, which received U.S. authorization in February 2021 for adults, may be given in cases where COVID-19 vaccine is inaccessible or approved or if a person is unwilling to give the other two, a meal. and prescription drugs. .
J&J is one of the three vaccines used in the United States.
The other two are from Moderna and Pfizer.
The use of weak J&J shots in high-income countries, hampered by reports of rare, potentially fatal blood clots, production issues, including accidental collision of a contractor, and concerns about its existence effective.
The pharmaceutical manufacturer last month revoked its forecast for the sale of the COVID-19 vaccine, citing high supply.
J&J did not respond to a request for comment following an FDA statement.
Case cases of thrombosis and thrombocytopenia (TTS), which includes blood clots associated with low platelet levels, have been reported previously in recipients of J&J vaccine.
The FDA in January then produced a fact sheet for J&J vaccines to include the risk of thrombocytopenia-fighting, months after a European Union pharmacist did the same.
The FDA on Thursday stated that the risk factor for TTS has the potential to limit the use of a single dose after reviewing a reported case.
The US Centers for Disease Control and Prevention in December recommended that Americans choose to receive mRNA from Pfizer and Moderna for the J&J vaccine because of a rare disease of the blood vessels.
About 18.7 million Americans have received the J&J COVID-19 vaccine compared to 217.5 million who received the Moderna vaccine and 340.6 million who received the Pfizer bomb, according to the CDC.
US bans use of J & J’s COVID in antiretroviral drugs – SABC Report
Source link US bans use of J & J’s COVID in antiretroviral drugs – SABC Report